Phio Pharmaceuticals
Phio Pharmaceuticals Corp.
4 Investors
Biotechnology
MARLBOROUGH, MA
Phio Pharmaceuticals Corp. is a biotechnology company specializing in the development of groundbreaking therapeutics, particularly in the field of immuno-oncology. Utilizing their proprietary technology platform, they focus on addressing unmet medical needs to potentially enhance cancer treatment outcomes.
Products & Team
PH-762
Cancer immunotherapeuticSeed
PH-762 is the flagship product candidate of Phio Pharmaceuticals, currently in clinical studies. It shows promising potential in enhancing cancer treatment by modulating immune responses to improve therapy outcomes.
Value Proposition
PH-762 addresses the critical need for improved cancer therapies by potentially enhancing the effectiveness of immune-oncology treatments.
Pain Points
Need for innovative cancer treatments and enhancement of therapeutic efficacy
Immune response modulationClinical study promising early results
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
MARLBOROUGH, MA
Primary headquarters
Funding History
Total Raised:
$626.8K
E
Option to Acquire, Security Offering
January 2025
$3.7M
Target
Progress
4%Raised
$152.5K
Target
$3.7M
#000112329225000031
E
Option to Acquire, Security Offering
January 2025
$5.0M
Target
Progress
4%Raised
$208.3K
Target
$5.0M
#000112329225000029
E
Option to Acquire, Security Offering
January 2025
$6.4M
Target
Progress
4%Raised
$265.9K
Target
$6.4M
#000112329225000027